June 7, 2017 / 8:13 PM / 3 months ago

BRIEF-Karyopharm doses first patient in pivotal phase 3 boston study

June 7 (Reuters) - Karyopharm Therapeutics Inc:

* Karyopharm doses first patient in pivotal phase 3 boston study evaluating selinexor in patients with relapsed/refractory multiple myeloma

* Karyopharm-Expects to include over 100 clinical sites internationally in boston study, to complete enrollment in 2018, with top-line data anticipated in 2019

* Karyopharm therapeutics inc- intend to use boston study data to support an nda filing for selinexor for treatment of relapsed or refractory myeloma Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below